Document:

rgmp_ex991.htm

EXHIBIT 10.1
  
 ASSIGNMENT AND ASSUMPTION AGREEMENT
 
 THIS ASSIGNMENT AND ASSUMPTION AGREEMENT (this “Assignment Agreement”) is made effective as of December 23, 2021 (the “Effective Time”), notwithstanding the actual date of execution hereof, by and between the following parties:
  
 	 Assignor: 
	SevenScore Pharmaceuticals, LLC, a Delaware limited liability company (hereinafter referred to as “Assignor”);
	  
	  

	 Assignee: 
	Regnum Corp., a Nevada Corporation (hereinafter referred to as “Assignee”); and
	  
	  

	 Counterparty: 
	CytoDyn Inc., a Delaware Corporation (hereinafter referred to as “Counterparty”)

  
 WITNESSETH:
  
 WHEREAS, on December 17, 2019, Counterparty and Vyera Pharmaceuticals, LLC, a Delaware limited liability company (hereinafter referred to as “Vyera”), entered into to that certain commercialization and license agreement listed in Exhibit A (as amended or otherwise modified from time to time, hereinafter referred to as the “Commercialization and License Agreement”); 
  
 WHEREAS, on December 17, 2019, Counterparty and Vyera, entered into that certain supply agreement listed in Exhibit A (as amended or otherwise modified from time to time, hereinafter referred to as the “Supply Agreement”); 
  
 WHEREAS, on October 29, 2020, Counterparty, Vyera and Assignor entered into that certain assignment and assumption agreement pursuant to which Vyera transferred, assigned and delegated to Assignor all of Vyera’s right, title, interest and duties in, to and under the Commercialization and License Agreement and the Supply Agreement and Assignor accepted such assignment and assumed any and all duties, obligations and liabilities of Vyera under the Commercialization and License Agreement and the Supply Agreement;
  
 WHEREAS, Assignor desires to transfer, assign and delegate to Assignee all of Assignor’s right, title, interest and duties in, to and under the Commercialization and License Agreement and the Supply Agreement and Assignee desires to accept such assignment and to assume any and all duties, obligations and liabilities of Assignor under the Commercialization and License Agreement and the Supply Agreement pursuant to the terms of this Assignment Agreement; 
  
 WHEREAS, Assignor and Assignee are Affiliates, as defined in the Commercialization and License Agreement and the terms of the Commercialization and License Agreement provide that Assignor may assign the Commercialization and License Agreement without Counterparty’s consent to an Affiliate; and
  
 WHEREAS, the terms of the Supply Agreement provide that no assignment of Assignor’s rights in and to the Supply Agreement to an Affiliate shall be effective without the prior written consent of Counterparty.
   
 	 
	
	

	 

  
 NOW, THEREFORE, in consideration of the foregoing premises and the following mutual promises, covenants, representations and agreements contained herein, the adequacy of which is hereby acknowledged:
   
 	 (A)  
	 Assignor and Assignee agree as follows:

	  
	  
	  

	  
	 1. 
	Assignor hereby assigns unto Assignee, effective as of the Effective Time, the Commercialization and License Agreement and all of Assignor’s rights, title and interest thereunder, and hereby assigns and delegates to Assignee all of Assignor’s liabilities, duties and obligations in, to and under the Commercialization and License Agreement as of the Effective Time hereof.
	  
	  
	  

	  
	 2. 
	Assignee hereby assumes the Commercialization and License Agreement and covenants and agrees effective as of the Effective Time, to observe, pay, perform, and discharge all duties, obligations and liabilities imposed upon Assignor under the Commercialization and License Agreement in every way as if the Assignee was a party thereto, including, but not limited to, all financial and indemnification obligations
	  
	  
	  

	  
	 3. 
	The delivery of this Assignment Agreement by Assignor to Counterparty shall serve as an official notice of the assignment of the Commercialization and License Agreement in the terms described above. In the event that Counterparty does not execute this Assignment Agreement for purposes of Section B below, this Assignment Agreement shall remain valid as it relates to Assignor and Assignee in connection with this Section A.
	  
	  
	  

	  
	 4. 
	The Commercialization and License Agreement is hereby amended to specifically make reference to the following being Assignee’s current address and all further communication delivered pursuant to the Agreement to Assignee shall be delivered to such address:

    
 	  
	 Regnum Corp.

	  
	 Attention:
	 [***]

	  
	 Address:
	 600 Third Avenue, 19th Floor

	  
	  
	 New York, NY 10016

	  
	 Email:
	 [***]

	  
	  
	  

	  
	with a copy to: 	 [***]

	  
	 Address:
	 600 Third Avenue, 19th Floor

	  
	  
	 New York, NY 10016

	  
	 Email:
	 [***]

  
 	 
	2
	

	 

  
 	 (B)
	 Assignor, Counterparty and Assignee agree as follows:

	  
	  
	  

	  
	 1.
	 Assignor hereby assigns unto Assignee, effective as of the Effective Time, the Supply Agreement and all of Assignor’s rights, title and interest thereunder, and hereby assigns and delegates to Assignee all of Assignor’s liabilities, duties and obligations in, to and under the Supply Agreement as of the Effective Time hereof.

	  
	  
	  

	  
	 2.
	 Counterparty hereby consents and agrees to the assignment of the Supply Agreement from Assignor to Assignee as of the Effective Time and Assignee hereby assumes the Supply Agreement and covenants and agrees effective as of the Effective Time, to observe, pay, perform, and discharge all duties, obligations and liabilities imposed upon Assignor under the Supply Agreement in every way as if the Assignee was a party thereto, including, but not limited to, all financial and indemnification obligations

	  
	  
	  

	  
	 3.
	 The Supply Agreement is hereby amended to specifically make reference to the following being Assignee’s current address and all further communication delivered pursuant to the Agreement to Assignee shall be delivered to such address:

   
 		 Regnum Corp.

	  
	 Attention:
	 [***]

	  
	 Address:
	 600 Third Avenue, 19th Floor

	  
	  
	 New York, NY 10016

	  
	 Email:
	 [***]

	  
	  
	  

	  
	with a copy to: 	 [***]

	  
	 Address:
	 600 Third Avenue, 19th Floor

	  
	  
	 New York, NY 10016

	  
	 Email:
	 [***]

    
 This Assignment Agreement may be executed in multiple counterparts and shall be legal and binding upon the parties hereto the same as if each and every named party executed all counterparts. If any one or more of the provisions of this Assignment Agreement is held to be invalid, illegal or unenforceable, in whole or in part, or in any respect, then such provision or provisions only will be deemed to be null and void and of no force or effect and will not affect any other provision of this Agreement, and the remaining provisions of this Agreement will remain operative and in full force and effect and will in no way be affected, prejudiced or disturbed.
  
 A facsimile of this Assignment Agreement shall be legal and binding the same as an originally executed version hereof. This Assignment Agreement is binding upon and shall inure to the benefit of Assignor, Assignee and Counterparty, their respective successors and assigns.
  
 [Signature Page Follows]
   
 	 
	3
	

	 

  
 IN WITNESS WHEREOF, the parties have executed this Assignment Agreement effective as of the Effective Time.
   
 	  
	 ASSIGNOR:
	  

	  
	  
	  

	  
	 SEVENSCORE PHARMACEUTICALS, LLC
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Anne Kirby
	  

	  
	 Name:
	 Anne Kirby
	  

	  
	 Title:
	 CEO
	  

	  
	  
	 1/3/2022
	  

	  
	  
	  
	  

	  
	 ASSIGNEE:
  
 REGNUM CORP.
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Anne Kirby
	  

	  
	 Name:
	 Anne Kirby
	  

	  
	 Title:
	 CEO
	  

	  
	  
	 1/3/2022
	  

	  
	  
	  
	  

	  
	 COUNTERPARTY:
   
 CYTODYN INC.
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Nader Pourhassan
	  

	  
	 Name: 
	 Nader Pourhassan
	  

	  
	 Title:
	 President & CEO
	  

   
 SIGNATURE PAGE TO ASSIGNMENT AND ASSUMPTION AGREEMENT
  
 	 
	 4

	

	 

  
 EXHIBIT A
  
 Attached Agreements
  
 1. Commercialization and License Agreement, effective as of December 17, 2019, by and between the Assignor and Counterparty (the “Commercialization and License Agreement”).
  
 2. Supply Agreement, effective as of December 17, 2019, by and between the Assignor and Counterparty (the “Supply Agreement”).rgmp_ex102.htm

EXHIBIT 10.2
   
 CONTRIBUTION AGREEMENT
  
 THIS CONTRIBUTION AGREEMENT (this “Contribution Agreement”) is made effective as of January 3, 2022 (the “Effective Date”), notwithstanding the actual date of execution hereof, by and among SevenScore Pharmaceuticals, LLC, a Delaware limited liability company (“SevenScore”), Regnum Corp., a Nevada corporation (“Regnum”) and Phoenixus AG, a corporation organized under the laws of Switzerland and holder of (a) 99% of the issued and outstanding shares of Regnum, and (b) 100% of the issued and outstanding membership interest units of SevenScore (“Phoenixus”).
  
 WITNESSETH:
  
 WHEREAS, SevenScore, Regnum and CytoDyn Inc. (“CytoDyn”) have entered into that certain Assignment and Assumption Agreement, dated as of the date hereof (the “Assignment and Assumption Agreement”), pursuant to which (A) SevenScore assigned and delegated to Regnum all of SevenScore’s right, title, interest and duties in, to and under (i) that certain commercialization and license agreement listed on Exhibit A hereto (as amended or otherwise modified from time to time, hereinafter referred to as the “Commercialization and License Agreement”), and (ii) that certain supply agreement listed on Exhibit A hereto (as amended or otherwise modified from time to time, hereinafter referred to as the “Supply Agreement,” and together with the Commercialization and License Agreement, the “CytoDyn Assets”), and (B) Regnum accepted the CytoDyn Assets and assumed any and all duties, obligations and liabilities of SevenScore under the Commercialization and License Agreement and the Supply Agreement (collectively, the “Assumed Liabilities,” and such transactions described in sections (A) and (B) of this paragraph, the “Transfer”);
  
 WHEREAS, for United States federal income tax purposes, it is intended that the Transfer shall qualify as a tax-free transfer of property from SevenScore to Regnum under Section 351 of the Internal Revenue Code of 1986, as amended (the “Code”).
  
 NOW, THEREFORE, in consideration of the foregoing premises and the following mutual promises, covenants, representations and agreements contained herein, the adequacy of which is hereby acknowledged, the parties hereto hereby agree as follows:
  
 ARTICLE I  
  
 CONTRIBUTION
  
 1.1 Contribution. In consideration for the CytoDyn Assets assigned to Regnum pursuant to the Assignment and Assumption Agreement, Phoenixus hereby transfers to SevenScore, on behalf of Regnum, 4,094,023 shares of Regnum, with an agreed upon fair market value of $1,637,609.00 (the “Contributed Shares”), and it is hereby acknowledged and agreed that the consideration for the transfer of the CytoDyn Assets from SevenScore to Regnum is the Contributed Shares and the assumption by Regnum of the Assumed Liabilities.
   
 	 
	
	

	 

  
 1.2 Tax Free Transfer. From and after the date of this Contribution Agreement, each party hereto shall use reasonable efforts to cause the Transfer to qualify as a tax-free transfer of property under Section 351 of the Code for United States federal income tax purposes and for purposes of any income tax imposed by a State or political subdivision thereof, including but not limited to filing any tax or information returns consistent with this Contribution Agreement and attaching any statements to tax returns as may be required pursuant to Treasury Regulation Sections 1.351-3 of the Code, and shall not knowingly take any action or cause any action to be taken which could reasonably be expected to prevent the Transfer from qualifying as a tax-free transfer of property under Sections 351 of the Code for United States federal income tax purposes and for purposes of any income tax imposed by a State or political subdivision thereof.
  
 1.3 Further Assurances. Each party shall, and shall cause its respective affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Contribution Agreement.
  
 ARTICLE II  
  
 MISCELLANEOUS
  
 2.1. Counterparts. This Contribution Agreement may be executed in multiple counterparts and shall be legal and binding upon the parties hereto the same as if each and every named party executed all counterparts. Delivery of an executed counterpart of a signature page to this Contribution Agreement by facsimile, email or other electronic transfer shall be effective as delivery of a manually executed counterpart to this Contribution Agreement.
  
 2.2. Severability. If any one or more of the provisions of this Contribution Agreement is held to be invalid, illegal or unenforceable, in whole or in part, or in any respect, then such provision or provisions only will be deemed to be null and void and of no force or effect and will not affect any other provision of this Contribution Agreement, and the remaining provisions of this Contribution Agreement will remain operative and in full force and effect and will in no way be affected, prejudiced or disturbed.
  
 2.3. Successors and Assigns. This Contribution Agreement may not be assigned to either party hereto without the prior written consent of the other party. Subject to the foregoing sentence, all of the terms and provisions of this Contribution Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and permitted assigns.
  
 2.4. Governing Law. All matters relating to or arising out of this Contribution Agreement (whether sounding in contract, tort of otherwise) will be governed by and construed in accordance with the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule of any jurisdiction that would cause the application of the laws of any jurisdiction other than the State of Delaware.
  
 [Signature Page Follows]
  
 	 
	2
	

	 

  
 IN WITNESS WHEREOF, the parties have executed this Contribution Agreement effective as of the Effective Time.
  
 	 	SEVENSCORE PHARMACEUTICALS, LLC 	
	 	 	 	 
		By:	/s/ Anne Kirby	
	  
	 Name:
	Anne Kirby	 
	 	Title:	CEO	 
	 	 	 	 
	  
	 REGNUM CORP.
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Anne Kirby
	  

	  
	 Name:
	 Anne Kirby
	  

	  
	 Title:
	 CEO
	  

	  
	  
	  
	  

	  
	 PHOENIXUS AG
	  

	  
	  
	  
	  

	  
	 By:
	 /s/ Averill Powers
	  

	  
	 Name: 
	 Averill Powers
	  

	  
	 Title:
	 CEO
	  

   
 SIGNATURE PAGE TO CONTRIBUTION AGREEMENT
  
 	 
	 3

	

	 

  
 EXHIBIT A
  
 CytoDyn Assets
  
 1. Commercialization and License Agreement, effective as of December 17, 2019, by and between Sevenscore and CytoDyn (the “Commercialization and License Agreement”).
  
 2. Supply Agreement, effective as of December 17, 2019, by and between Sevenscore and CytoDyn (the “Supply Agreement”).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]